摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1R,2S,4R,5R,6R)-2-((4-methoxybenzyl)oxy)-4-methyl-3,7-dioxabicyclo[4.1.0]heptan-5-ol | 1268624-99-2

中文名称
——
中文别名
——
英文名称
(1R,2S,4R,5R,6R)-2-((4-methoxybenzyl)oxy)-4-methyl-3,7-dioxabicyclo[4.1.0]heptan-5-ol
英文别名
4-methoxybenzyl 2,3-anhydro-6-deoxy-α-D-allopyranoside
(1R,2S,4R,5R,6R)-2-((4-methoxybenzyl)oxy)-4-methyl-3,7-dioxabicyclo[4.1.0]heptan-5-ol化学式
CAS
1268624-99-2
化学式
C14H18O5
mdl
——
分子量
266.294
InChiKey
ZRNUHHRZPVAGGV-OJGWYHNPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.08
  • 重原子数:
    19.0
  • 可旋转键数:
    4.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    60.45
  • 氢给体数:
    1.0
  • 氢受体数:
    5.0

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Total Synthesis and Biological Evaluation of the Glycosylated Macrocyclic Antibiotic Mangrolide A
    作者:Hiromu Hattori、Joel Roesslein、Patrick Caspers、Katja Zerbe、Hideki Miyatake-Ondozabal、Daniel Ritz、Georg Rueedi、Karl Gademann
    DOI:10.1002/anie.201805770
    日期:2018.8.20
    The macrocyclic antibiotic mangrolide A has been described to exhibit potent activity against a number of clinically important Gram‐negative pathogens. Reported is the first enantioselective total synthesis of mangrolide A and derivatives. Salient features of this synthesis include a highly convergent macrocycle preparation, stereoselective synthesis of the disaccharide moiety, and two β‐selective
    大环抗生素甜菊内酯A被描述为对许多临床上重要的革兰氏阴性病原体表现出有效的活性。报道了第一个对映选择性全合成芒果内酯A及其衍生物。该合成的显着特征包括高度收敛的大环化合物制备,二糖部分的立体选择性合成以及两个β选择性糖基化。芒果内酯A及其类似物的合成能够重新检查其对细菌病原体的活性,并且仅观察到最小的活性。
  • [EN] AMPHOTERICIN B DERIVATIVE WITH REDUCED TOXICITY<br/>[FR] DÉRIVÉ D'AMPHOTÉRICINE B À TOXICITÉ RÉDUITE
    申请人:UNIV ILLINOIS
    公开号:WO2014165676A1
    公开(公告)日:2014-10-09
    Provided are an amphotericin B (AmB) derivative with an improved therapeutic index over amphotericin B, pharmaceutical compositions comprising the AmB derivative, methods of making the AmB derivative and the pharmaceutical composition, and their use in methods of inhibiting growth of a yeast or fungus and treating a yeast or fungal infection. The amphotericin B derivative, denoted C2'deOAmB, differs from the parent compound in that it lacks the hydroxyl group at the 2' position on mycosamine. This difference in structure results in (i) retained capacity to bind ergosterol and inhibit growth of yeast, (ii) greatly reduced capacity to bind cholesterol, and (iii) essentially no toxicity to human cells.
    提供了一种改进了治疗指数的两性霉素B(AmB)衍生物,其中包括该AmB衍生物的制药组合物,制备该AmB衍生物和制药组合物的方法,以及它们在抑制酵母或真菌生长和治疗酵母或真菌感染的方法中的使用。该两性霉素B生物被标记为C2'deOAmB,与母体化合物不同的是,它在蘑菇糖胺上的2'位置缺乏羟基团。这种结构上的差异导致(i)保留了结合麦角固醇和抑制酵母生长的能力,(ii)大大降低了结合胆固醇的能力,(iii)对人类细胞基本没有毒性。
  • C2′-OH of Amphotericin B Plays an Important Role in Binding the Primary Sterol of Human Cells but Not Yeast Cells
    作者:Brandon C. Wilcock、Matthew M. Endo、Brice E. Uno、Martin D. Burke
    DOI:10.1021/ja403255s
    日期:2013.6.12
    Amphotericin B (AmB) is a clinically vital antimycotic but is limited by its severe toxicity. Binding ergosterol, independent of channel formation, is the primary mechanism by which AmB kills yeast, and binding cholesterol may primarily account for toxicity to human cells. The leading structural model predicts that the C2' hydroxyl group on the mycosamine appendage is critical for binding both sterols. To test this, the C2'-OH was synthetically deleted, and the sterol binding capacity of the resulting derivative, C2'deOAmB, was directly characterized via isothermal titration calorimetry. Surprisingly, C2'deOAmB binds ergosterol and, within the limits of detection of this experiment, does not bind cholesterol. Moreover, C2'deOAmB is nearly equipotent to AmB against yeast but, within the limits of detection of our assays, is nontoxic to human cells in vitro. Thus, the leading structural model for AmB/sterol binding interactions is incorrect, and C2'deOAmB is an exceptionally promising new antifungal agent
查看更多